Metalloproteinases MMP-9, MMP-2 and their tissue inhibitors TIMP-1, TIMP-2 in peripheral transbronchial lung biopsies of patients with sarcoidosis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 10, 2009, Pages 628-635

  Piotrowski, Wojciech J ^a   Nawrocka Kunecka, Agnieszka ^b   Antczak, Adam ^a   Marczak, Jerzy ^a   Biernacki, Romuald ^b   Kordek, Piotr ^c   Kurmanowska, Zofia ^a   Górski, Paweł ^a  

^a Medical University of Lodz Klinika Pneumonologii i Alergologii   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c Hospital of the Ministry of Interior Affairs and Administration   (Poland)

Author keywords

Metalloproteinases (MMPs); Sarcoidosis; Tissue inhibitors of MMPs; Trans bronchial lung biopsy

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG PARENCHYMA; LUNG SARCOIDOSIS; MALE; PROTEIN EXPRESSION; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY;

EID: 72249094369     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.789     Document Type: Article

References (30)

1. Stemankovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003; 200: 448-464. (Pubitemid 36818245)
2. Garbisa S, Baffin M, Daga-Gordini D, et al. Transient expression of type IV collagenolytic metalloproteinase by human mononuclear phagocytes. J Biol Chem. 1986; 261: 2369-2375. (Pubitemid 17205175)
3. Emonard H, Takiya C, Dreze S, et al. Interstitial collagenase (MMP-1), gelatinase (MMP-2) and stromefysin (MMP-3) released by human fibroblasts cultured on acellular sarcoid granulomas (sarcoid matrix complex, SMC). Matrix. 1989; 9: 382-388. (Pubitemid 20013817)
4. Desmard M, Amara N, Lanone S, et al. Carbon monoxide reduces the expression and activity of matrix metalloproteinases 1 and 2 in alveolar epithelial cells. Cell Mol Biol. 2005; 30: 403-408. (Pubitemid 41596318)
5. Fukada Y, Ishizaki M, Kudoh S, et al. Localization of matrix metalloproteinases-1, -2 and -9 and tissue inhibitor of metalloproteinase-2 in interstitial king disease. Lab Invest. 1998; 78: 687-689.
6. Peters CA, Freeman MR, Fenandez CH, et al. Dysregutated proteolytic balance as the basis of excess extracellular matrix in fibrotic disease. Am J Physiol. 1997; 732: 11-21.
7. Chapman HA. Disorders of lung matrix remodeling. J Clin Invest. 2004; 113: 148-157.
8. Levi E, Fridman R, Miao HQ, et al. Matrix metalloproteinase-2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA. 1996; 93: 7069-7074. (Pubitemid 26243503)
9. Fiore E, Fusco C, Romero P, et al. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene. 2002; 21: 5213-5223. (Pubitemid 34948133)
10. Opdenakker G, Van des Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001; 22: 571-579.
11. Sheu BC, Hsu SM, Ho HN, et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001; 61: 237-242.
12. Lemjabbar H, Gosset P, Lechapt-Zalcman E, et al. Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis. Effects of steroid and immunosuppressive treatment. Am J Respir Cell Mol Biol. 1999; 20: 903-913. (Pubitemid 129540849)
13. Agostini C, Garbisa R, Trentin L, et al. Pulmonary alveolar macrophages from patents with active sarcoidosis express type IV collagenolytic proteinase. An enzymatic mechanism for influx of mononuclear phagocytes at sites of disease activity. J Clin Invest. 1989; 84: 605-612. (Pubitemid 19196994)
14. Fireman E, Kraiem Z, Sade O, et al. Induced sputum-retrieved matrix metalloproteinase 9 and tissue metalloproteinase inhibitor 1 in granulomatous disease. Clin Exp Immunol. 2002; 130: 331-337. (Pubitemid 35286223)
15. Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase-9/ tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med. 1998; 158: 1945-1950. (Pubitemid 29008837)
16. Mattos W, Lim S, Russell R, et al. Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroid. Chest. 2002; 122: 1543-1552. (Pubitemid 35366062)
17. Bosse M, Chakir J, Rouabhia M, et al. Serum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am J Respir Crit Care Med. 1999; 159: 596-602. (Pubitemid 29084886)
18. Fiedorczyk M, Klimczuk PA, Sierakowski S, et al. [Serum concentration of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) correlates with markers of the disease activity in early rheumatoid arthritis]. Pol Arch Med Wewn. 2006; 115: 13-17. Polish. (Pubitemid 44047458)
19. Klimiuk PA, Sierakowski S, Chwiećko J. [Serum interieukin 6 (IL-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis]. Pol Arch Med Wewn. 2003; 109: 119-123. Polish. (Pubitemid 36378241)
20. Statement on sarcoidosis. The joint statement of ATS, ERS and WASOG. Am J Respir Crit Care Med. 1999; 160: 736-755.
21. Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment of sarcoidosis. Am J Respir Crit Care Med. 1994; 149: 893-898.
22. Sones M, Israel H. Course and prognosis of sarcoidosis. Am J Med. 1960; 29: 84-93.
23. Gilman MJ, Wang KP. Transbronchial lung biopsy in sarcoidosis: an approach to determine the optimal number of biopsies. Am Rev Respir Dis. 1980; 122: 721-724. (Pubitemid 11194218)
24. British Thoracic Society guidelines on diagnostic flexible bronchoscopy. British Thoracic Society Bronchoscopy Guidlines Committee, a Subcommittee of the Standards of Care Committee of the British Thoracic Society. Thorax. 2001; 56 (Suppl 1): i1-i21.
25. Tomalak W, Antczak A, Boros P, et a. [Polish Respiratory Society Standards for Spirometry Testing]. Pneumonol Alergol Pol. 2006; 72 (Suppl 2): 1-32. Polish.
26. Choi KH, Lee HB, Jeong MY, et al. The role of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in cryptogenic organizing pneumonia. Chest. 2002; 121: 1478-1485.
27. O'Connor C, Odium C, van Breda A, et al. Collagenase and fibronectin in bronchoalveolar lavage fluid in patients with sarcoidosis. Thorax. 1988; 43: 393-400.
28. Henry MT, McMahon K, Mackarel AJ, et al. Matrix metalloproteinase and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur Respir J. 2002; 20: 1220-1227. (Pubitemid 35331881)
29. Shimada A, Koga T, Oskita Y, et al. Reduced pulmonary function is associated with enhanced inflammation and tissue inhibitor of metalloproteinase 1 concentration in the bronchoalveolar lavage fluid of patients with lung parenchymal sarcoidosis. Kurume Med J. 2008; 55: 13-17.
30. Gonzalez AA, Segura AM, Horiba K, et al. Matrix metalloproteinases and their tissue inhibitors in the lesions of cardiac and pulmonary sarcoidosis: an immunohistochemical study. Hum Pathol. 2002; 33: 1158-1164. (Pubitemid 36020063)